Scrub Typhus: Comprehensive Disease-Characteristics Report

Executive summary

Scrub typhus is an acute, potentially fatal, mite-borne infection caused principally by the obligate intracellular bacterium Orientia tsutsugamushi. Humans are accidental dead-end hosts; larval trombiculid mites (“chiggers”), especially Leptotrombidium species, transmit infection, while small mammals—particularly rodents—support the enzootic cycle. Approximately 2 billion people live in at-risk regions and the commonly cited burden is about 1 million cases annually, although weak surveillance and non-standardized diagnostics make this estimate uncertain. The central lesion is disseminated infection of endothelial and mononuclear-phagocyte compartments, producing vasculitis-like endothelial dysfunction, capillary leak, inflammation, and potentially respiratory, hepatic, cardiovascular, renal, or neurologic failure. (lynnette2024scrubtyphusdiagnostics pages 1-2, adhikari2024editorialscrubtyphus pages 2-3, ravishankar2024rickettsialinfectionsprevalence pages 4-5)

The most consequential recent therapeutic development is the 2023 INTREST randomized trial: intravenous doxycycline plus azithromycin reduced a composite of death at day 28, persistent organ complications at day 7, or fever at day 5 to 33%, versus 47% with doxycycline and 48% with azithromycin alone. Mortality itself remained similar at 11–13%, so the benefit principally concerned earlier resolution of fever/organ complications rather than demonstrated survival benefit. (varghese2023intravenousdoxycyclineazithromycin pages 4-6, varghese2023intravenousdoxycyclineazithromycin pages 21-23, varghese2023intravenousdoxycyclineazithromycin pages 8-10)

The following table provides a knowledge-base-ready synopsis; details and evidentiary qualifications follow.

Table: This table condenses the most actionable scrub typhus facts for a disease knowledge base, including clinical, epidemiologic, mechanistic, diagnostic, and treatment domains. It also flags which classical human genetics fields are not applicable for this infectious disease and suggests ontology mappings without inventing uncertain IDs.

1. Disease information

Definition and names

Scrub typhus is an acute undifferentiated febrile illness caused mainly by O. tsutsugamushi. Synonyms include tsutsugamushi disease, tsutsugamushi fever, mite-borne typhus, and historically Japanese river fever. Despite its historical grouping with rickettsioses, the organism belongs to Orientia, not Rickettsia. A recent review describes it as a “vector-borne, zoonotic disease” that becomes diagnostically difficult when the characteristic eschar is absent. (lynnette2024scrubtyphusdiagnostics pages 1-2, chaturvedi2025spatiotemporalepidemiologyand pages 2-3)

Identifiers

• ICD-10/ICD-10-CM: A75.3, Typhus fever due to Rickettsia tsutsugamushi; the legacy organism name persists in the label.
• ICD-11: classified under rickettsioses/other specified rickettsioses; the exact browser code should be validated against the current ICD-11 release before ingestion.
• MeSH: Scrub Typhus; entry terms include tsutsugamushi disease.
• MONDO: a scrub-typhus concept exists, but the exact numerical MONDO identifier was not recoverable from the retrieved primary literature and should be resolved directly through the current MONDO release rather than inferred.
• OMIM/Orphanet: no causal-disease entry is expected in the Mendelian-disease sense; this is an acquired infectious disease, not a monogenic disorder.

The evidence summarized here is aggregated disease-level evidence from reviews, cohorts, trials, and experimental studies—not patient-level EHR data.

2. Etiology, risk, and protective factors

Cause and transmission

The immediate cause is inoculation of Orientia by an infected chigger. The principal agent is O. tsutsugamushi, a gram-negative, non-motile, non-capsulated, pleomorphic obligate intracellular bacterium. More than 20 genotypes have been described in India alone, and antigenic/genomic diversity is a major obstacle to universal serodiagnostics and vaccines. (chaturvedi2025spatiotemporalepidemiologyand pages 2-3, ravishankar2024rickettsialinfectionsprevalence pages 4-5)

Chiggers acquire and maintain Orientia within mite populations; rodents and other small mammals serve as feeding hosts and ecological reservoirs. Humans do not ordinarily transmit infection onward. Risk is therefore ecological rather than hereditary: agricultural work, paddy cultivation, plantations, brush or scrub vegetation, contact with mite-infested soil, and residence or travel in endemic rural landscapes increase exposure. Temperature, humidity, rainfall, rodent suitability, and season influence transmission. (adhikari2024editorialscrubtyphus pages 2-3, ravishankar2024rickettsialinfectionsprevalence pages 4-5, NCT02876367 chunk 1)

Demographic and host risk

All ages can be affected. Exposure patterns often make farmers, field workers, military personnel, and rural residents overrepresented. Older age and comorbidity may worsen outcomes, but the retrieved evidence does not support a universal sex ratio. Pregnancy is clinically important because maternal infection can be severe and influences antibiotic selection.

Genetic risk and gene–environment interaction

There are no causal human genes, pathogenic germline variants, inheritance pattern, penetrance, carrier frequency, founder mutations, or chromosomal abnormalities. Limited candidate-gene literature has examined immune-response loci such as TLR2, TLR4, and HSP70, but the relevant primary article was not available in full text during this retrieval; these associations should not be treated as validated clinical susceptibility markers. Exposure to infected mites overwhelmingly dominates risk, and no host genotype is used for diagnosis, prognosis, or treatment selection.

Protective factors

Protection is primarily environmental and behavioral: avoiding mite habitats, using protective clothing and repellents, clearing vegetation around camps or dwellings, and prompt recognition and treatment. No reproducible protective human allele is established. Natural immunity is strain-limited and may be short-lived; antigenic heterogeneity limits cross-protection.

3. Phenotypes

The incubation period is usually 6–21 days. Disease begins acutely with fever, headache, myalgia, chills, malaise, and sometimes cough or gastrointestinal symptoms. In an India meta-analysis, fever/AUFI had a pooled prevalence of 97%, while headache, chills, myalgia, and arthralgia individually or collectively occurred in approximately 33–56%. (ravishankar2024rickettsialinfectionsprevalence pages 4-5, chaturvedi2025spatiotemporalepidemiologyand pages 7-8)

Principal phenotype annotations

• Fever—acute, nearly universal, variable severity; suggested HPO: Fever.
• Eschar—painless necrotic crust at the bite site, often hidden in axillae, groin, inframammary or genital regions. Pooled prevalence was about 26% in the India analysis, whereas reports range from 7–80% across populations. Absence does not exclude infection. Suggested HPO: Eschar or closest available necrotic-skin-lesion term. (vashishtha2025scrubtyphusupdate pages 6-7, chaturvedi2025spatiotemporalepidemiologyand pages 7-8)
• Maculopapular rash—often appears near the end of week 1 and spreads from trunk to limbs; variably present. Suggested HPO: Maculopapular rash.
• Regional lymphadenopathy—typically near the inoculation site; suggested HPO: Lymphadenopathy.
• Hepatic disease—hepatomegaly 46% and hepatic dysfunction 44% in the cited meta-analysis; transaminase elevation and hyperbilirubinemia are common laboratory abnormalities. Suggested HPO: Hepatomegaly, Elevated hepatic transaminases, Hyperbilirubinemia. (chaturvedi2025spatiotemporalepidemiologyand pages 7-8)
• Respiratory disease—interstitial pneumonitis, hypoxemia, pulmonary edema/capillary leak, and ARDS. Respiratory involvement occurred in 62% of the severe-disease trial population. Suggested HPO: Interstitial pulmonary disease, Hypoxemia, Acute respiratory distress syndrome. (varghese2023intravenousdoxycyclineazithromycin pages 4-6)
• Cardiovascular disease—hypotension/shock, myocarditis, arrhythmia, heart failure, and occasionally myocardial infarction. Cardiovascular involvement occurred in 42% of severe trial participants. Suggested HPO: Hypotension, Myocarditis, Cardiac arrhythmia, Heart failure. (adhikari2024editorialscrubtyphus pages 2-3, varghese2023intravenousdoxycyclineazithromycin pages 4-6)
• Renal disease—acute kidney injury from hypoperfusion, endothelial injury, inflammation, and multiorgan dysfunction; 30% in the severe trial. Suggested HPO: Acute kidney injury, Elevated serum creatinine. (varghese2023intravenousdoxycyclineazithromycin pages 4-6)
• Neurologic disease—meningitis, meningoencephalitis, delirium, seizures, tremor, cerebellitis, hearing loss, or altered consciousness; 20% had neurologic involvement in the severe trial. Suggested HPO: Meningitis, Encephalitis, Seizure, Delirium, Tremor, Sensorineural hearing impairment. (vashishtha2025scrubtyphusupdate pages 6-7, varghese2023intravenousdoxycyclineazithromycin pages 4-6)
• Hematologic abnormalities—thrombocytopenia and, in severe cases, coagulopathy; suggested HPO: Thrombocytopenia.

Phenotypes are acute and progressive when untreated rather than stable or lifelong. Quality-of-life studies using EQ-5D or SF-36 were not identified. During acute severe disease, ICU admission, ventilation, encephalopathy, and organ failure profoundly impair function; survivors treated promptly generally recover, although neurologic, auditory, renal, or cardiac sequelae may persist in a minority.

4. Genetic and molecular information

Human genetics

Classical disease-genetics fields are not applicable: no causal HGNC gene, OMIM gene, ACMG-classified pathogenic variant, germline/somatic distinction, allele frequency, modifier gene, chromosomal abnormality, or clinically actionable pharmacogenomic marker defines scrub typhus. WES, WGS, panels, CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing have no role in routine diagnosis.

Pathogen genomics

O. tsutsugamushi has an unusually repetitive, rearranged genome with poor strain-to-strain gene-order collinearity. Dual RNA-seq indicated that virulence differences between Karp and UT176 strains related substantially to differential expression, not simply gene presence or absence. The Karp strain induced an IL33–NOS3–FAS-associated anoikis program in endothelial cells, whereas UT176 produced a more IL6-dominant response. The experiment used a high multiplicity of infection (~30:1), limiting direct physiological extrapolation. (mikagospodorz2020dualrnaseqof pages 9-9)

The ongoing START trial incorporates whole-genome sequencing of isolates to relate genotype to clearance, relapse, and antimicrobial susceptibility—an example of pathogen precision medicine rather than inherited human genetics. (NCT03083197 chunk 1)

5. Environmental and infectious-agent information

The infectious agent is Orientia, transmitted through chigger-infested environments. Farming, scrub vegetation, forest edges, soil contact, rainfall, humidity, temperature, and rodent abundance shape risk. A One Health framework is therefore appropriate. Tobacco, alcohol, diet, and exercise are not established causal factors, although nutritional status and comorbidity could influence severity nonspecifically. (adhikari2024editorialscrubtyphus pages 2-3, ravishankar2024rickettsialinfectionsprevalence pages 4-5)

The traditional “tsutsugamushi triangle” extends broadly from northern Asia/Japan through South and Southeast Asia to northern Australia, but recent literature emphasizes transmission or Orientia-like organisms beyond this historical boundary. This changing geography may reflect improved detection, travel, land-use change, vector-range shifts, climate, and genuine emergence. (vashishtha2025scrubtyphusupdate pages 11-12, lynnette2024scrubtyphusdiagnostics pages 1-2, adhikari2024editorialscrubtyphus pages 2-3)

6. Mechanism and pathophysiology

Causal chain

Chigger bite → dermal inoculation and eschar → intracellular invasion/replication → lymphatic and hematogenous dissemination → endothelial and mononuclear-phagocyte infection → interferon- and cytokine-rich inflammation plus endothelial dysfunction → capillary leak, microvascular injury, tissue hypoxia, and organ-specific inflammation → pneumonitis/ARDS, hepatitis, myocarditis/shock, AKI, meningoencephalitis, or multiorgan failure.

Cells and pathways

Orientia preferentially infects endothelial cells, but dendritic cells, monocytes, and macrophages are also involved. Suggested Cell Ontology mappings are endothelial cell, monocyte, macrophage, dendritic cell, and microglial cell; suggested GO biological processes include response to bacterium, inflammatory response, type I interferon signaling, cytokine-mediated signaling, apoptotic process, leukocyte activation, and regulation of vascular permeability. (lynnette2024scrubtyphusdiagnostics pages 1-2, tantibhedhyangkul2011orientiatsutsugamushistimulates pages 1-2)

Human/in-vitro transcriptomics: Infection altered more than 4,500 genes in healthy-donor monocytes, upregulating type-I-interferon and interferon-stimulated genes, M1-polarization features, and apoptosis-related genes. Patient mononuclear cells showed 613 upregulated genes, including interferon-related signatures. The authors’ abstract concluded that “interferon-mediated activation of monocytes and their subsequent polarization into an M1 phenotype appear critical.” (tantibhedhyangkul2011orientiatsutsugamushistimulates pages 1-2)

Endothelial dual RNA-seq: Karp-infected HUVECs showed IL33 approximately 5.1 log-fold higher than UT176-infected cells and activation of IL33–NOS3–FAS-associated anoikis, while UT176 favored IL6-mediated inflammation. Mouse validation linked these strain-specific programs to relative virulence. (mikagospodorz2020dualrnaseqof pages 9-9)

Neuropathogenesis—mouse and in-vitro evidence: The 2023 brain RNA-seq study found enrichment of IFN responses, defense against bacteria, immunoglobulin-mediated immunity, IL-6/JAK–STAT, and TNF/NF-κB signaling, accompanied by blood–brain-barrier-disruption genes and activated, cytokine-producing microglia. Its abstract states that the work highlights “excessive IFN responses, microglial activation, and BBB dysregulation.” These results are mechanistically persuasive but remain predominantly murine and require human CNS validation. (liang2023braintranscriptomicsreveal pages 1-2)

No consistent disease-specific epigenomic, lipidomic, or clinically validated metabolomic signature was identified. Single-cell and spatial-transcriptomic evidence remains limited. No CRISPR-based host-dependency screen has yet produced an actionable therapeutic target in the retrieved evidence.

7. Anatomical structures affected

The skin is the inoculation site and eschar location. Dissemination affects vascular endothelium throughout the body. Major secondary organs are the lungs, liver, heart, kidneys, brain/meninges, spleen, lymph nodes, and bone marrow/blood. Suggested UBERON mappings include skin, blood vessel endothelium, lung, liver, heart, kidney, brain, meninges, spleen, and lymph node. No characteristic lateralization exists. (vashishtha2025scrubtyphusupdate pages 6-7, varghese2023intravenousdoxycyclineazithromycin pages 4-6)

At the subcellular level, Orientia is cytosolic after host-cell entry and escape from its vacuole; bacterial ribosomes are pharmacologic targets. No primary human mitochondrial, lysosomal, nuclear, or ER genetic defect underlies disease.

8. Temporal development

Onset may occur in children or adults and is acute, not congenital. After 6–21 days of incubation, fever and systemic symptoms begin; rash may emerge near the end of week 1. Untreated disease can broaden during week 2 into pulmonary, neurologic, cardiac, renal, or hepatic complications. (vashishtha2025scrubtyphusupdate pages 6-7, ravishankar2024rickettsialinfectionsprevalence pages 4-5)

The clinically important intervention window is early febrile illness, before organ dysfunction. PCR is most useful during early bacteremia; serologic sensitivity rises later. Effective antibiotics typically produce defervescence over the following days. Relapse or persistent infection can occur, but chronic symptomatic lifelong disease is not the usual course. In an intradermally infected mouse model, viable organisms or the 47-kDa target remained detectable in organs through 84 days, showing biological persistence even after acute illness; human significance remains incompletely defined.

9. Inheritance and population epidemiology

There is no Mendelian inheritance, penetrance, expressivity, anticipation, germline mosaicism, founder effect, or carrier state. Population differences principally reflect ecology, occupation, surveillance, healthcare access, and circulating strain/vector distributions.

Approximately 2 billion people are considered at risk and roughly 1 million annual cases are commonly cited. These are modeled/legacy estimates rather than complete surveillance counts. (lynnette2024scrubtyphusdiagnostics pages 1-2)

A 2025 systematic review covering India from 2003–2023 identified 47,650 cases and a 5% case-fatality rate among 35,243 evaluable cases, with notable increases after 2010 and peaks in 2019 and 2022. Although published in 2025, its observation window supplies recent 2023 epidemiology. (chaturvedi2025spatiotemporalepidemiologyand pages 2-3)

A completed South India cohort enrolled 32,566 people across approximately 40 villages and monitored symptomatic, serologic, and complicated infections through two seasons, while also trapping rodents to characterize spatial-temporal risk. (NCT04506944 chunk 1, NCT04506944 chunk 2)

10. Diagnostics

Clinical suspicion and criteria

Suspect scrub typhus in an endemic-area resident or traveler with acute fever, headache/myalgia, thrombocytopenia or transaminitis, an eschar, or unexplained pulmonary, neurologic, renal, cardiac, or hepatic dysfunction. The eschar is highly informative but not invariably present and may be concealed. There is no universally standardized clinical case definition.

Laboratory methods

1. PCR/qPCR: detects Orientia DNA and is most useful early, before antibiotics reduce bacteremia. Eschar material can remain highly productive; one recent editorial summarized 100% positivity in eschar samples and 94% in buffy coat in highlighted work. Targets include 47-kDa, 56-kDa/TSA, and other conserved loci; claims of “100% detection” for individual target sets should not be generalized across settings. (ravishankar2024rickettsialinfectionsprevalence pages 7-8, adhikari2024editorialscrubtyphus pages 2-3)
2. IgM ELISA: practical and widely implemented; becomes more useful after antibodies develop. Endemic-background antibodies and locally inappropriate cutoffs can cause false positives.
3. Indirect immunofluorescence assay: commonly treated as a reference serologic method, but dependence on subjective interpretation, paired sera, antigen panels, and locally validated cutoffs limits standardization. Prototype Karp/Gilliam/Kato antigens may miss local diversity. (lynnette2024scrubtyphusdiagnostics pages 1-2, chaturvedi2025spatiotemporalepidemiologyand pages 2-3)
4. Rapid immunochromatographic tests: useful near the point of care but variable; one review cited approximately 70% sensitivity. (chaturvedi2025spatiotemporalepidemiologyand pages 2-3)
5. Weil–Felix: inexpensive but insufficiently sensitive/specific and should not be preferred where validated ELISA/PCR is available; nevertheless, it accounted for about 61% of tests in the India literature synthesis, illustrating a real-world implementation gap. (chaturvedi2025spatiotemporalepidemiologyand pages 7-8)
6. Metagenomic sequencing: potentially useful in atypical or diagnostically unresolved cases, but cost and infrastructure preclude routine use.

QuEST (NCT06675110) enrolled 345 participants in Thailand beginning July 17, 2024 to compare insulated isothermal PCR with qPCR/IFA, directly addressing decentralized rapid molecular diagnosis. (NCT06675110 chunk 1)

Imaging, ECG/echocardiography, EEG, CSF examination, renal/liver tests, and chest imaging assess complications rather than establish etiology. Biopsy is rarely necessary; pathology may show endothelial infection, perivascular inflammation, interstitial pneumonitis, and focal necrosis.

Differential diagnosis and screening

Differentials include dengue, malaria, leptospirosis, enteric fever, murine/spotted-fever rickettsioses, hantavirus, viral hepatitis, influenza/COVID-19, bacterial sepsis, and meningoencephalitis. No population, newborn, carrier, prenatal, or genetic screening is indicated. Targeted fever surveillance in endemic seasons is the appropriate public-health analogue.

11. Outcome and prognosis

Early appropriate antibiotics usually produce full recovery. Delay permits multiorgan dysfunction and increases ICU use and death. In severe trial participants, organ involvement was respiratory 62%, hepatic 54%, cardiovascular 42%, renal 30%, and neurologic 20%. Trial-defined severe disease included hypoxemia/infiltrates, bilirubin >2 mg/dL, creatinine >2 mg/dL, hypotension/myocarditis/arrhythmia, seizures or meningoencephalitis, or profound thrombocytopenia. (varghese2023intravenousdoxycyclineazithromycin pages 4-6, varghese2023intravenousdoxycyclineazithromycin pages 21-23)

Despite treatment, 28-day mortality in INTREST was 11% with doxycycline, 12% with azithromycin, and 13% with combination therapy. Thus, combination therapy improved the composite recovery endpoint but did not establish lower mortality. Adverse prognostic features include delayed therapy, shock, ARDS, myocarditis, AKI, encephalopathy, high organism burden, and multiple-organ involvement. (varghese2023intravenousdoxycyclineazithromycin pages 10-11, varghese2023intravenousdoxycyclineazithromycin pages 21-23)

Five- or ten-year survival metrics are not meaningful for this acute infection. Standardized long-term disability and quality-of-life data are sparse.

12. Treatment

Uncomplicated disease

Doxycycline is the conventional first-line agent; azithromycin is an effective alternative and is generally favored in pregnancy. Chloramphenicol is effective but limited by marrow toxicity and pregnancy/infant concerns. Rifampicin can be active but should be used cautiously where tuberculosis is prevalent because monotherapy can select rifampicin resistance. Fluoroquinolones are not dependable first-line agents. Supportive management includes oxygen/ventilation, hemodynamic support, renal replacement where needed, seizure management, and correction of fluid/electrolyte disturbances. (ravishankar2024rickettsialinfectionsprevalence pages 7-8, chaturvedi2025spatiotemporalepidemiologyand pages 2-3)

Severe disease: high-quality randomized evidence

INTREST was a multicenter, double-blind RCT in 794 modified-intention-to-treat patients aged ≥15 years with at least one involved organ system. Regimens were:

• IV doxycycline 200 mg twice on day 1, then 100 mg twice daily for 6 days;
• IV azithromycin 500 mg twice on day 1, then 500 mg daily for 6 days;
• both regimens together for 7 days. (varghese2023intravenousdoxycyclineazithromycin pages 6-8)

The primary composite occurred in 33% with combination therapy versus 47% with doxycycline (risk difference −13.3 percentage points; 95% CI −21.6 to −5.1; P=0.002) and 48% with azithromycin (−14.8 points; 95% CI −23.1 to −6.5; P<0.001). Monotherapies did not differ (P=0.73). The abstract’s conclusion was: “Combination therapy with intravenous doxycycline and azithromycin was a better therapeutic option.” (varghese2023intravenousdoxycyclineazithromycin pages 4-6)

Bacterial-DNA clearance was faster with combination therapy than doxycycline alone (HR 1.33, 95% CI 1.09–1.62). Grade ≥3 adverse events occurred in approximately 8–11% and were broadly similar across groups. The trial excluded children and pregnant patients, limiting direct generalization. DOI: 10.1056/NEJMoa2208449, published March 2023; Clinical Trials Registry–India CTRI/2018/08/015159. (varghese2023intravenousdoxycyclineazithromycin pages 10-11)

Suggested NCIT annotations: doxycycline treatment, azithromycin treatment, combination antimicrobial therapy, intravenous administration, supportive care, mechanical ventilation, renal replacement therapy.

Experimental/current studies

• START, NCT03083197: 177 participants; 7-day doxycycline versus 3-day doxycycline versus 3-day azithromycin; outcomes include fever clearance, relapse, PK/PD, MIC, WGS, and immune responses; active, not recruiting. (NCT03083197 chunk 1)
• NCT07513103: 27 adults; IV tigecycline (100-mg loading dose, then 50 mg every 12 hours for 5 days) versus oral doxycycline 100 mg every 12 hours for 7 days; completed January 2025, but definitive efficacy results were unavailable. (NCT07513103 chunk 1)
• NCT00351182: 92 adults with mild/moderate disease; five days of telithromycin 800 mg/day versus doxycycline 200 mg/day; completed. Telithromycin is not a routine preferred option. (NCT00351182 chunk 1)

There is no role for gene, cell, RNA, or immune-checkpoint therapy.

13. Prevention

No licensed broadly effective vaccine is available. Primary prevention comprises long trousers and sleeves, boots, repellents, avoidance of sitting directly on infested ground, vegetation management, and targeted vector-control measures. Because chiggers and small mammals occupy complex ecosystems, broad rodent eradication or indiscriminate insecticide use is unlikely to be sustainable.

Secondary prevention is rapid case recognition, regionally validated testing, and prompt empiric treatment when clinical suspicion is high. Tertiary prevention is early monitoring and treatment of hypoxemia, shock, renal failure, myocarditis, thrombocytopenia, and CNS disease. Routine antibiotic prophylaxis is not recommended for general populations, and there is no genetic counseling indication. (vashishtha2025scrubtyphusupdate pages 11-12, adhikari2024editorialscrubtyphus pages 2-3)

Vaccine development is hampered by marked strain diversity and incompletely durable heterologous immunity. Conserved antigens, multivalent constructs, and T-cell-focused strategies remain research priorities rather than current implementations.

14. Other species and natural disease

The natural cycle involves trombiculid mites and small mammals, especially rodents and shrews. Mites are both vectors and long-term maintenance hosts; mammals provide blood meals and ecological amplification. Humans are accidental hosts and scrub typhus is therefore zoonotic/vector-borne, but not normally transmitted directly from rodents or person to person. (lynnette2024scrubtyphusdiagnostics pages 1-2, NCT02876367 chunk 1)

Field study NCT02876367 enrolled approximately 1,200 participants and linked human, rodent, and mite Orientia genotypes to habitats using sequencing. This provides a real-world One Health implementation for identifying key hosts, vectors, and intervention sites. (NCT02876367 chunk 1)

Clinically recognized natural disease is chiefly human; overt scrub-typhus-like illness in domestic animal breeds is not well established. VBO breed annotation and orthologous human causal genes are therefore not applicable. NCBI Taxonomy identifiers should be assigned directly from current taxonomy records for O. tsutsugamushi, individual Leptotrombidium species, and locally sampled rodent species.

15. Model organisms

Mouse models

Intradermal inoculation of C57BL/6 mice more closely approximates natural cutaneous entry than intraperitoneal or intravenous challenge. After ear inoculation with 6×10⁴ organisms, mice developed fever at days 11–12, hypothermia/weight loss at days 14–19, and peak bacteremia, tissue burden, and pathology near day 14. Cytokines included CCL2, CCL3, IL-10, IL-6, IL-12, IFN-γ, CCL5, IL-1, TNF-α, and GM-CSF; organisms remained detectable through day 84. The model supports studies of acute disease, persistence, immunity, and vaccines, but it does not consistently reproduce the human eschar and differs in immune kinetics.

The 2023 severe-mouse model with brain RNA-seq recapitulates neuroinflammation, microglial activation, and BBB dysregulation, making it useful for neurologic pathogenesis but not a substitute for human CNS tissue evidence. (liang2023braintranscriptomicsreveal pages 1-2)

Nonhuman primates and cellular systems

Nonhuman primates can model eschar, fever, lymphadenopathy, and immune responses more faithfully, but cost, ethics, and limited availability constrain use. HUVEC/endothelial cultures, primary monocytes/macrophages, dendritic cells, and microglia permit mechanistic and drug studies. Their limitations include high experimental inocula, absent tissue architecture, and inability to reproduce systemic vascular disease. (mikagospodorz2020dualrnaseqof pages 9-9, tantibhedhyangkul2011orientiatsutsugamushistimulates pages 1-2)

Recent developments and expert interpretation

1. Therapy: The 2023 INTREST RCT is practice-changing for severe disease: dual IV doxycycline–azithromycin accelerates recovery compared with either alone, although equal mortality cautions against claiming a survival advantage. (varghese2023intravenousdoxycyclineazithromycin pages 10-11, varghese2023intravenousdoxycyclineazithromycin pages 4-6)
2. Mechanisms: The 2023 mouse brain-transcriptomics study links severe neurologic disease to excessive IFN activity, microglia, IL-6/JAK–STAT, TNF/NF-κB, and BBB disruption. This supplies testable mechanisms but not yet validated therapeutic targets. (liang2023braintranscriptomicsreveal pages 1-2)
3. Diagnostics: The 2024 diagnostic literature emphasizes a stage-adapted strategy—PCR early, serology later—and locally validated antigen panels/cutoffs. QuEST represents current implementation research on field-compatible iiPCR. (lynnette2024scrubtyphusdiagnostics pages 1-2, NCT06675110 chunk 1)
4. Epidemiology: Current authoritative opinion favors a One Health, spatially targeted response incorporating rainfall, temperature, land use, rodents, mites, and healthcare access rather than treating scrub typhus solely as a clinical rickettsiosis. (adhikari2024editorialscrubtyphus pages 2-3, NCT04506944 chunk 1)

Evidence and identifier caveats

PMIDs were requested, but the retrieved full-text records supplied DOIs and registry identifiers more consistently than PMIDs. To prevent database contamination, PMIDs not explicitly available in the evidence were not guessed. Exact MONDO, HPO, GO, CL, UBERON, CHEBI, and NCIT numerical identifiers likewise require validation against the current ontology releases; the report therefore supplies defensible term labels and only the independently supported ICD-10 code. Frequencies vary sharply by geography, case definition, disease severity, test timing, and referral setting; severe-hospital cohorts must not be used as population prevalence estimates.

References

1. (lynnette2024scrubtyphusdiagnostics pages 1-2): S. Cheryl Lynnette, Trishna Bora, Susmitha Perumalla, G. Karthick, Babban Jee, Gaurav Batra, M. Biswal, S. A. Khan, and J. A. J. Prakash. Scrub typhus diagnostics: the present and the future. Zoonoses, Jan 2024. URL: https://doi.org/10.15212/zoonoses-2023-0028, doi:10.15212/zoonoses-2023-0028. This article has 4 citations.

2. (adhikari2024editorialscrubtyphus pages 2-3): Prabhat Adhikari, Archana Shrestha, Suzanne M. Donovan, and Janak Koirala. Editorial: scrub typhus & its changing dynamics. Frontiers in Tropical Diseases, Nov 2024. URL: https://doi.org/10.3389/fitd.2024.1511950, doi:10.3389/fitd.2024.1511950. This article has 2 citations.

3. (ravishankar2024rickettsialinfectionsprevalence pages 4-5): Vigneshwaran Ravishankar, Shridhar Narayanan, and Radha Krishan Shandil. Rickettsial infections: prevalence and diagnosis of scrub typhus in india. Frontiers in Tropical Diseases, Sep 2024. URL: https://doi.org/10.3389/fitd.2024.1433013, doi:10.3389/fitd.2024.1433013. This article has 11 citations.

4. (varghese2023intravenousdoxycyclineazithromycin pages 4-6): George M. Varghese, Divya Dayanand, Karthik Gunasekaran, Debasree Kundu, Mukta Wyawahare, Navneet Sharma, Dhruva Chaudhry, Sanjay K. Mahajan, Kavitha Saravu, Blessed W. Aruldhas, Binu S. Mathew, Roshini G. Nair, Nalini Newbigging, Aswathy Mathew, Kundavaram P.P. Abhilash, Manisha Biswal, Ann H. Prasad, Anand Zachariah, Ramya Iyadurai, Samuel G. Hansdak, Sowmya Sathyendra, Thambu D. Sudarsanam, John A.J. Prakash, Abi Manesh, Alladi Mohan, Joel Tarning, Stuart D. Blacksell, Pimnara Peerawaranun, Naomi Waithira, Mavuto Mukaka, Phaik Yeong Cheah, John V. Peter, Ooriapadickal C. Abraham, and Nicholas P.J. Day. Intravenous doxycycline, azithromycin, or both for severe scrub typhus. The New England journal of medicine, 388 9:792-803, Mar 2023. URL: https://doi.org/10.1056/nejmoa2208449, doi:10.1056/nejmoa2208449. This article has 125 citations and is from a highest quality peer-reviewed journal.

5. (varghese2023intravenousdoxycyclineazithromycin pages 21-23): George M. Varghese, Divya Dayanand, Karthik Gunasekaran, Debasree Kundu, Mukta Wyawahare, Navneet Sharma, Dhruva Chaudhry, Sanjay K. Mahajan, Kavitha Saravu, Blessed W. Aruldhas, Binu S. Mathew, Roshini G. Nair, Nalini Newbigging, Aswathy Mathew, Kundavaram P.P. Abhilash, Manisha Biswal, Ann H. Prasad, Anand Zachariah, Ramya Iyadurai, Samuel G. Hansdak, Sowmya Sathyendra, Thambu D. Sudarsanam, John A.J. Prakash, Abi Manesh, Alladi Mohan, Joel Tarning, Stuart D. Blacksell, Pimnara Peerawaranun, Naomi Waithira, Mavuto Mukaka, Phaik Yeong Cheah, John V. Peter, Ooriapadickal C. Abraham, and Nicholas P.J. Day. Intravenous doxycycline, azithromycin, or both for severe scrub typhus. The New England journal of medicine, 388 9:792-803, Mar 2023. URL: https://doi.org/10.1056/nejmoa2208449, doi:10.1056/nejmoa2208449. This article has 125 citations and is from a highest quality peer-reviewed journal.

6. (varghese2023intravenousdoxycyclineazithromycin pages 8-10): George M. Varghese, Divya Dayanand, Karthik Gunasekaran, Debasree Kundu, Mukta Wyawahare, Navneet Sharma, Dhruva Chaudhry, Sanjay K. Mahajan, Kavitha Saravu, Blessed W. Aruldhas, Binu S. Mathew, Roshini G. Nair, Nalini Newbigging, Aswathy Mathew, Kundavaram P.P. Abhilash, Manisha Biswal, Ann H. Prasad, Anand Zachariah, Ramya Iyadurai, Samuel G. Hansdak, Sowmya Sathyendra, Thambu D. Sudarsanam, John A.J. Prakash, Abi Manesh, Alladi Mohan, Joel Tarning, Stuart D. Blacksell, Pimnara Peerawaranun, Naomi Waithira, Mavuto Mukaka, Phaik Yeong Cheah, John V. Peter, Ooriapadickal C. Abraham, and Nicholas P.J. Day. Intravenous doxycycline, azithromycin, or both for severe scrub typhus. The New England journal of medicine, 388 9:792-803, Mar 2023. URL: https://doi.org/10.1056/nejmoa2208449, doi:10.1056/nejmoa2208449. This article has 125 citations and is from a highest quality peer-reviewed journal.

7. (chaturvedi2025spatiotemporalepidemiologyand pages 7-8): Rini Chaturvedi, S. Hussain, Hayavadhan Sampath, M. Rahi, B. R. Mirdha, and Amit Sharma. Spatiotemporal epidemiology and clinical manifestations of two decades of scrub typhus in india: a systematic review and meta-analysis. BMJ Global Health, Aug 2025. URL: https://doi.org/10.1136/bmjgh-2025-018998, doi:10.1136/bmjgh-2025-018998. This article has 10 citations and is from a peer-reviewed journal.

8. (liang2023braintranscriptomicsreveal pages 1-2): Yuejin Liang, Aditi, Florence Onyoni, Hui Wang, Casey Gonzales, Piyanate Sunyakumthorn, Ping Wu, Parimal Samir, and Lynn Soong. Brain transcriptomics reveal the activation of neuroinflammation pathways during acute orientia tsutsugamushi infection in mice. Frontiers in Immunology, Jun 2023. URL: https://doi.org/10.3389/fimmu.2023.1194881, doi:10.3389/fimmu.2023.1194881. This article has 16 citations and is from a peer-reviewed journal.

9. (vashishtha2025scrubtyphusupdate pages 6-7): Ankur Vashishtha, Vivek Kumar, Gautam Panwar, Gaurav Kausik, Samaniya Baig, Prigya Sharma, and Rajesh Yadav. Scrub typhus update: a re‑emerging global threat beyond the tsutsugamushi triangle and the physiological ramifications of scrub typhus infection (review). World Academy of Sciences Journal, Feb 2025. URL: https://doi.org/10.3892/wasj.2025.322, doi:10.3892/wasj.2025.322. This article has 15 citations.

10. (mikagospodorz2020dualrnaseqof pages 9-9): Bozena Mika-Gospodorz, Suparat Giengkam, Alexander J. Westermann, Jantana Wongsantichon, Willow Kion-Crosby, Suthida Chuenklin, Loo Chien Wang, Piyanate Sunyakumthorn, Radoslaw M. Sobota, Selvakumar Subbian, Jörg Vogel, Lars Barquist, and Jeanne Salje. Dual rna-seq of orientia tsutsugamushi informs on host-pathogen interactions for this neglected intracellular human pathogen. Nature Communications, Jul 2020. URL: https://doi.org/10.1038/s41467-020-17094-8, doi:10.1038/s41467-020-17094-8. This article has 67 citations and is from a highest quality peer-reviewed journal.

11. (tantibhedhyangkul2011orientiatsutsugamushistimulates pages 1-2): Wiwit Tantibhedhyangkul, Thanavadee Prachason, Duangdao Waywa, Adil El Filali, Eric Ghigo, Wanna Thongnoppakhun, Didier Raoult, Yupin Suputtamongkol, Christian Capo, Chanin Limwongse, and Jean-Louis Mege. Orientia tsutsugamushi stimulates an original gene expression program in monocytes: relationship with gene expression in patients with scrub typhus. PLoS Neglected Tropical Diseases, 5:e1028, May 2011. URL: https://doi.org/10.1371/journal.pntd.0001028, doi:10.1371/journal.pntd.0001028. This article has 85 citations and is from a domain leading peer-reviewed journal.

12. (chaturvedi2025spatiotemporalepidemiologyand pages 2-3): Rini Chaturvedi, S. Hussain, Hayavadhan Sampath, M. Rahi, B. R. Mirdha, and Amit Sharma. Spatiotemporal epidemiology and clinical manifestations of two decades of scrub typhus in india: a systematic review and meta-analysis. BMJ Global Health, Aug 2025. URL: https://doi.org/10.1136/bmjgh-2025-018998, doi:10.1136/bmjgh-2025-018998. This article has 10 citations and is from a peer-reviewed journal.

13. (NCT06675110 chunk 1): QuEST - Quick and Easy Scrub Typhus Diagnostic Tools. University of Oxford. 2024. ClinicalTrials.gov Identifier: NCT06675110

14. (varghese2023intravenousdoxycyclineazithromycin pages 6-8): George M. Varghese, Divya Dayanand, Karthik Gunasekaran, Debasree Kundu, Mukta Wyawahare, Navneet Sharma, Dhruva Chaudhry, Sanjay K. Mahajan, Kavitha Saravu, Blessed W. Aruldhas, Binu S. Mathew, Roshini G. Nair, Nalini Newbigging, Aswathy Mathew, Kundavaram P.P. Abhilash, Manisha Biswal, Ann H. Prasad, Anand Zachariah, Ramya Iyadurai, Samuel G. Hansdak, Sowmya Sathyendra, Thambu D. Sudarsanam, John A.J. Prakash, Abi Manesh, Alladi Mohan, Joel Tarning, Stuart D. Blacksell, Pimnara Peerawaranun, Naomi Waithira, Mavuto Mukaka, Phaik Yeong Cheah, John V. Peter, Ooriapadickal C. Abraham, and Nicholas P.J. Day. Intravenous doxycycline, azithromycin, or both for severe scrub typhus. The New England journal of medicine, 388 9:792-803, Mar 2023. URL: https://doi.org/10.1056/nejmoa2208449, doi:10.1056/nejmoa2208449. This article has 125 citations and is from a highest quality peer-reviewed journal.

15. (vashishtha2025scrubtyphusupdate pages 11-12): Ankur Vashishtha, Vivek Kumar, Gautam Panwar, Gaurav Kausik, Samaniya Baig, Prigya Sharma, and Rajesh Yadav. Scrub typhus update: a re‑emerging global threat beyond the tsutsugamushi triangle and the physiological ramifications of scrub typhus infection (review). World Academy of Sciences Journal, Feb 2025. URL: https://doi.org/10.3892/wasj.2025.322, doi:10.3892/wasj.2025.322. This article has 15 citations.

16. (ravishankar2024rickettsialinfectionsprevalence pages 7-8): Vigneshwaran Ravishankar, Shridhar Narayanan, and Radha Krishan Shandil. Rickettsial infections: prevalence and diagnosis of scrub typhus in india. Frontiers in Tropical Diseases, Sep 2024. URL: https://doi.org/10.3389/fitd.2024.1433013, doi:10.3389/fitd.2024.1433013. This article has 11 citations.

17. (NCT02876367 chunk 1): The Clinical Epidemiology of Scrub Typhus in Humans, Chiggers and Rodents. University of Oxford. 2016. ClinicalTrials.gov Identifier: NCT02876367

18. (NCT03083197 chunk 1): Scrub Typhus Antibiotic Resistance Trial. University of Oxford. 2017. ClinicalTrials.gov Identifier: NCT03083197

19. (NCT04506944 chunk 1): The Epidemiology of Rickettsial Infections in South India: Cohort Study. London School of Hygiene and Tropical Medicine. 2020. ClinicalTrials.gov Identifier: NCT04506944

20. (NCT04506944 chunk 2): The Epidemiology of Rickettsial Infections in South India: Cohort Study. London School of Hygiene and Tropical Medicine. 2020. ClinicalTrials.gov Identifier: NCT04506944

21. (varghese2023intravenousdoxycyclineazithromycin pages 10-11): George M. Varghese, Divya Dayanand, Karthik Gunasekaran, Debasree Kundu, Mukta Wyawahare, Navneet Sharma, Dhruva Chaudhry, Sanjay K. Mahajan, Kavitha Saravu, Blessed W. Aruldhas, Binu S. Mathew, Roshini G. Nair, Nalini Newbigging, Aswathy Mathew, Kundavaram P.P. Abhilash, Manisha Biswal, Ann H. Prasad, Anand Zachariah, Ramya Iyadurai, Samuel G. Hansdak, Sowmya Sathyendra, Thambu D. Sudarsanam, John A.J. Prakash, Abi Manesh, Alladi Mohan, Joel Tarning, Stuart D. Blacksell, Pimnara Peerawaranun, Naomi Waithira, Mavuto Mukaka, Phaik Yeong Cheah, John V. Peter, Ooriapadickal C. Abraham, and Nicholas P.J. Day. Intravenous doxycycline, azithromycin, or both for severe scrub typhus. The New England journal of medicine, 388 9:792-803, Mar 2023. URL: https://doi.org/10.1056/nejmoa2208449, doi:10.1056/nejmoa2208449. This article has 125 citations and is from a highest quality peer-reviewed journal.

22. (NCT07513103 chunk 1): Jin Soo Lee. Clinical Effectiveness of Tigecycline for Scrub Typhus.. Jin Soo Lee. 2022. ClinicalTrials.gov Identifier: NCT07513103

23. (NCT00351182 chunk 1): Dong-Min Kim. Controlled Trial: 5-day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus. Dong-Min Kim. 2005. ClinicalTrials.gov Identifier: NCT00351182

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.